NCT03645187RecruitingPhase 4
Evaluation of Anticancer Effect of Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer
Sherief Abd-Elsalam1 site in 1 country50 target enrollmentStarted: August 1, 2018Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- number of patients with improved radiology
Study Overview
Brief Summary
The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer
Detailed Description
The primary aim of the study is to evaluate the anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •advanced colorectal cancer
Exclusion Criteria
- •cerebral metastases
- •other malignancy
- •H pylori infection
- •thromboembolism
Arms & Interventions
FOLFERI
Active Comparator
FOLFERI regien
Intervention: FOLFERI (Drug)
FOLFERI and celecoxib
Active Comparator
FOLFERI and celecoxib
Intervention: Folferi and celecoxib (Drug)
Outcomes
Primary Outcomes
number of patients with improved radiology
Time Frame: 6 months
number of patients with improved radiology
Secondary Outcomes
No secondary outcomes reported
Investigators
Sherief Abd-Elsalam
PhDTropical Medicine
Tanta University
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast CancerBreast CancerNCT00135018Organisation for Oncology and Translational Research
Completed
Phase 2
Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By SurgeryColorectal CancerNCT00336960Vanderbilt-Ingram Cancer Center24
Completed
Phase 1
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder CancerBladder CancerNCT02885974Baylor College of Medicine22
Terminated
Phase 2
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung CancerHead and Neck CancerLung CancerNCT00527982M.D. Anderson Cancer Center1
Terminated
Phase 2
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung CancerLung CancerNCT00520845Vanderbilt-Ingram Cancer Center23